The DEA's plan to list kratom as a Schedule I controlled substance would make researching the possible opioid substitute much more difficult.
Dr. Roger McIntyre suggests that the clinical relevance of cognitive dysfunction for any individual patient can only be adjudicated on a case-by-case basis.
The researchers observed between-group differences between real and sham acupuncture treatment.
Studies have found only small improvements in treating depression with Omega-3s and have been of low-quality.
Patients with psychosis and addiction disorders responded moderately better to disorder-specific treatment.
Patients in coordinated care remained in treatment longer and experienced greater improvements in their symptoms, compared with standard-care patients.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Sertraline Effective for Treating Depression in Vascular Cognitive Impairment
- Hospitalization Rates in Schizophrenia—Lurasidone vs Quetiapine
- Ketamine-Induced Dissociative Symptoms Predict Antidepressant Response
- First Nonopioid Drug Approved for Managing Opioid Withdrawal Symptoms
- Review Examines the Effectiveness of Antidepressants for Insomnia
- Video Games and Exercise as Alternative Therapies for ADHD
- How Parents Can Enhance Autism Treatment: Use of Intervention Strategies at Home
- Electroconvulsive Therapy Effective in Children With Autism
- Comorbid Autism Spectrum Disorder and OCD: Challenges in Diagnosis and Treatment
- The Cutting Edge of Schizophrenia Research: VR as Treatment for Psychosis
- Antidepressant Use May Be Linked With Sustained Risk for Weight Gain
- Language Used in Medical Record Can Affect Patient Care
- Family History of Psychiatric Disorders an Important Predictor of Postpartum Psychiatric Illness
- Increased Risk for Type 2 Diabetes in Adolescents, Young Adults With ADHD
- Worse Cognitive Outcomes Associated With CMV Antibodies Following ART for HIV